FDA Extends Zanzalintinib NDA Review by Three Months; New PDUFA Date March 3, 2027
EXEL sits 70% above its 52-week low of $33.755.
Summary
FDA extended the zanzalintinib NDA review period by three months, moving the PDUFA action date to March 3, 2027, after classifying Exelixis' updated data submission as a major amendment.
Key Events · Product Development and Regulatory · EXEL
-
FDA Extends Zanzalintinib Review
FDA extended the NDA review period for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer by three months.
-
New PDUFA Date Set
The updated Prescription Drug User Fee Act action date is March 3, 2027.
-
Major Amendment Classification
FDA deemed Exelixis' updated safety and efficacy data submission a major amendment, triggering the extension.
-
Pipeline Timing Impact
The delay pushes back a potential approval decision for zanzalintinib, a key pipeline asset, by approximately three months.
Analysis · EXEL · Life Sciences
The FDA has extended its review of Exelixis' zanzalintinib NDA for metastatic colorectal cancer by three months after deeming the company's updated safety and efficacy data a major amendment. The new PDUFA action date is March 3, 2027. This delays a potential approval decision and pushes back a key pipeline catalyst, though the extension reflects an active information request rather than a rejection. The stock is trading near its 52-week high, so the delay may temper near-term enthusiasm around the zanzalintinib opportunity.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1993 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EXEL was trading at $57.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.2B. The 52-week trading range was $33.76 to $59.72. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.